Raymond James & Associates Vir Biotechnology, Inc. Transaction History

Raymond James & Associates

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	BUY	$7.63 - $12.66 $565,482 - $938,270	74,113 New	74,113 $659,000
Q2 2021 Aug 11, 2021	SELL	$38.75 - $51.0 $154,031 - $202,725	-3,975 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$26.34 - $83.07 $357,565 - $1.13 Million	-13,575 Reduced 77.35%	3,975 $204,000
Q4 2020 Feb 12, 2021	BUY	$25.51 - $43.38 $105,866 - $180,027	4,150 Added 30.97%	17,550 $470,000
Q3 2020 Nov 04, 2020	BUY	$28.28 - $53.6 $5,825 - $11,041	206 Added 1.56%	13,400 $460,000
Q2 2020 Jul 28, 2020	BUY	$27.89 - $47.86 $367,980 - $631,464	13,194 New	13,194 $541,000

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $922M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.